VTE

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Retrieved on: 
Tuesday, March 12, 2024
Deep vein thrombosis, Pulmonary embolism, VTE, Incidence, Sequela, CAVA, Patient, Post-thrombotic syndrome, Research, PTS, DVT, Randomized controlled trial, Safety, FACS, American Venous Forum, Data, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.

Key Points: 
  • IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.
  • The interim results are the largest prospective, multi-center two-year dataset in deep vein thrombosis (DVT) since the ATTRACT trial and confirm the excellent safety, effectiveness, and long-term outcomes of the ClotTriever system in real-world DVT patients.
  • Patients had low incidence of independently adjudicated safety events related to rethrombosis, with only 5.0% and 8.4% at 30-days and 6 months, respectively.
  • We remain committed to establishing the ClotTriever and FlowTriever systems as standard of care for deep vein thrombosis and pulmonary embolism (PE) patients.”

Inari Medical Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Acquisition, VTE, Randomized controlled trial, Traction, Marketing, Average cost, Growth, GAAP, Organization, Patient, RCT, Net, Research, Bank

Revenue was $132.1 million for the fourth quarter of 2023, up 22.6% compared to $107.8 million for the fourth quarter of 2022.

Key Points: 
  • Revenue was $132.1 million for the fourth quarter of 2023, up 22.6% compared to $107.8 million for the fourth quarter of 2022.
  • Gross profit was $115.1 million for the fourth quarter of 2023, compared to $94.6 million for the fourth quarter of 2022.
  • Gross margin was 87.1% for the fourth quarter of 2023, compared to 87.8% for the fourth quarter of 2022.
  • Operating expenses for the fourth quarter of 2023 were $124.4 million, compared to $100.5 million for the fourth quarter of 2022.

Medicus IT Partners with Eagle Physicians & Associates to Drive Digital Transformation with mCare™

Retrieved on: 
Tuesday, February 27, 2024
VTE, Growth, Health, Knowledge, Physician, Partnership, Nursing

This collaboration marks a significant milestone in both organization's commitment to innovation and excellence in healthcare IT infrastructure.

Key Points: 
  • This collaboration marks a significant milestone in both organization's commitment to innovation and excellence in healthcare IT infrastructure.
  • By leveraging Medicus' expertise in healthcare IT solutions and its next-generation managed services offering, Eagle Physicians sees this partnership as one that aims to drive efficiency, improve outcomes, and ensure data security in the healthcare ecosystem with a focus on patient experience.
  • Medicus has been providing managed services for over twenty-five years that include IT helpdesk support, advanced engineering, infrastructure monitoring, remediation, management services, application support, and strategic Virtual Technology Executive™ (VTE) consulting services.
  • Their commitment to excellence and expertise closely aligns with our vision for digital innovation and success which can only position us for future growth."

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

Retrieved on: 
Monday, February 12, 2024
Essential medicines, CE, Rivaroxaban, VTE, Anticoagulant, INR, Roche, Edoxaban, Direct factor Xa inhibitors, PAD, Stroke, Moyamoya disease, Risk, CAD, Ventricular fibrillation, Health, Patient, Labs, Coronary thrombosis, Diagnosis, Laboratory, Coronary artery disease

"Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.

Key Points: 
  • "Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.
  • "These numbers and our growing understanding of these diseases are leading to a sharp rise in global demand for direct oral anticoagulants.
  • We want to help labs meet this increased need for testing to better inform patient care.
  • These tests can be used for both assessing the anti-Xa activity of heparin therapy as well as the three authorised Factor Xa inhibitors.

Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance

Retrieved on: 
Tuesday, January 9, 2024
Coronary thrombosis, Patient, Traction, Annual report, RCT, VTE, FLAME, Randomized controlled trial, Isabella Tree, Growth, Pharmaceutical industry

IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.

Key Points: 
  • IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.
  • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be at least $132.0 million, up approximately 22% year-over-year.
  • Preliminary unaudited revenue for the full year 2023 is expected to be at least $493.5 million, up approximately 29% over the full year 2022.
  • Further detail will be provided when Inari reports its financial results for the fourth quarter and full year 2023.

Endovascular Engineering's Hēlo™ Thrombectomy System Receives IDE Approval to Start ENGULF Pivotal Trial for the Treatment of Pulmonary Embolism

Retrieved on: 
Thursday, January 11, 2024
IDE, Coronary thrombosis, Patient, Cardiac catheterization, University, Interventional cardiology, Safety, VTE, MPH, Piedmont Hospital, Pulmonary embolism, Pharmaceutical industry

The approval of the IDE follows the successful completion of the company's 25-patient feasibility study.

Key Points: 
  • The approval of the IDE follows the successful completion of the company's 25-patient feasibility study.
  • "We are excited to be at the forefront of this innovative procedure with the completion of the ENGULF feasibility study.
  • This significant achievement sets the stage for definitive results in the ENGULF pivotal trial.
  • Embarking on our ENGULF pivotal trial is a significant step, further validating the system's safety and efficacy.

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Artery, Heart, INN, Risk, Hypertension, Population, Embolism, Rivaroxaban, Moyamoya disease, Death, Thrombus, Coronary artery disease, Chest pain, Vein, Facial muscles, Anatomy, ACS, IIA, Knee, ATC, Clopidogrel, DVT, Bleeding, Disease, Ageing, Atrial fibrillation, ASA, Safety, Leg, Medical Subject Headings, Hip, Peripheral artery disease, Pulmonary embolism, Thrombin, Diabetes, International, CAD, Language, Ventricular fibrillation, Tablet, Select, Aspirin, Patient, Acute coronary syndrome, Coronary thrombosis, Blood, Brain, VTE, Recurrence, European Medicines Agency, Ticlopidine, Deep vein thrombosis, PAD, Generic drug

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Artery, Pregnancy, Coronary thrombosis, Estetrol, INN, Risk, Pearl, Progesterone, Woman, IIA, ATC, Health system, Bleeding, International, Headache, Ageing, Language, VTE, Mouth, Tablet, Dysmenorrhea, Acne, Birth control, European Medicines Agency, Blister, Menstrual cycle, Pearl Index, Select, Birth, Patient, Vein, Safety, Cancer, Checklist, Anatomy, Vaginal bleeding, Internal bleeding, Ovulation

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Retrieved on: 
Sunday, November 26, 2023
MET, Neoplasm, Lung cancer, ESMO, HER2, Aes, RECIST, SGT, PRS, ILD, G5, EGFR, G2, Cetuximab, VTE, Congress, Head, Abstract, NRG1, Biomarker, Poster, Oncology, Investment, Patient, Causality, Safety, Webcast, NSCLC, G3, Pharmaceutical industry

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress website. The abstracts highlight updated interim clinical data from expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the ESMO Asia Congress 2023 taking place in Singapore December 1-3, 2023.

Key Points: 
  • ET
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress website.
  • The abstracts highlight updated interim clinical data from expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the ESMO Asia Congress 2023 taking place in Singapore December 1-3, 2023.
  • Updated clinical data, with additional patients and a later data cutoff date, will be included in the mini-oral presentation on NSCLC and the poster on HNSCC at ESMO Asia next week.
  • An abstract for an encore of a recent ESMO Congress 2023 presentation on zenocutuzumab interim clinical data from the eNRGy trial and Early Access Program in patients with NRG1 fusion (NRG1+) NSCLC has also been accepted for presentation at ESMO Asia.

Medicus Unveils Revolutionary Virtual Technology Executive™ Service, Redefining Healthcare IT Managed Services

Retrieved on: 
Tuesday, December 19, 2023
Health, VTE, Medicus, Growth, Investment, Organization, Intelligence, AFL–CIO, Management

This groundbreaking platform will redefine healthcare IT managed services, empowering organizations to achieve unprecedented efficiency, strategic alignment, growth, and, ultimately, business transformation.

Key Points: 
  • This groundbreaking platform will redefine healthcare IT managed services, empowering organizations to achieve unprecedented efficiency, strategic alignment, growth, and, ultimately, business transformation.
  • Unlike traditional vCIO services, Medicus' Virtual Technology Executive™ service takes a holistic approach, empowering healthcare organizations to move from the conventional run mode to a critical path of growth and transformation.
  • "Medicus' Virtual Technology Executive™ service empowers healthcare organizations to embrace technology and innovation for improved patient care and operational excellence," said Medicus' CEO Chris Jann.
  • Medicus' Virtual Technology Executive™ Service:
    Strategic Guidance: Unparalleled direction to align technology initiatives with overall business goals.